Drug name - Juvisync
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(3 years from now) | |
| CN1861077A | MERCK SHARP DOHME | As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine |
Oct, 2008
(13 years ago) | |
| CN1524082A | MERCK SHARP DOHME | As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine |
Jul, 2022
(2 months ago) | |
| CN1290848C | MERCK SHARP DOHME | As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine |
Jul, 2022
(2 months ago) | |
| CN1832949A | MERCK SHARP DOHME | Dipeptidyl Peptidase Iv Inhibitor Of Phosphate |
Jun, 2024
(1 year, 8 months from now) | |
| CN100430397C | MERCK SHARP DOHME | Dipeptidyl Peptidase Iv Inhibitor Of Phosphate |
Jun, 2024
(1 year, 8 months from now) | |
| IN200400026P4 | MERCK SHARP DOHME | Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes |
Jul, 2022
(2 months ago) | |
| IN209816B | MERCK SHARP DOHME | Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes |
Jul, 2022
(2 months ago) | |
| EP2292232B1 | MERCK SHARP DOHME | Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii |
Jul, 2022
(2 months ago) | |
| EP1625847B1 | MERCK SHARP DOHME | Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine |
Jul, 2022
(2 months ago) | |
| EP1625847A1 | MERCK SHARP DOHME | Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine |
Jul, 2022
(2 months ago) | |
| EP2292232A1 | MERCK SHARP DOHME | Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii |
Jul, 2022
(2 months ago) | |
| EP1654263B1 | MERCK SHARP DOHME | Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
Jun, 2024
(1 year, 8 months from now) | |
| EP1654263A1 | MERCK SHARP DOHME | Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
Jun, 2024
(1 year, 8 months from now) | |
| EP1654263B2 | MERCK SHARP DOHME | Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
Jun, 2024
(1 year, 8 months from now) | |
| EP1412357B1 | MERCK SHARP DOHME | Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes |
Aug, 2028
(5 years from now) | |
| EP1412357A1 | MERCK SHARP DOHME | Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6699871
(Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(3 months from now) | |
|
US7125873
(Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(3 months from now) | |
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Oct, 2026
(4 years from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 10MG;EQ 50MG BASE | TABLET;ORAL | Discontinued |
| 10MG;EQ 100MG BASE | TABLET;ORAL | Discontinued |
| 20MG;EQ 50MG BASE | TABLET;ORAL | Discontinued |
| 20MG;EQ 100MG BASE | TABLET;ORAL | Discontinued |
| 40MG;EQ 50MG BASE | TABLET;ORAL | Discontinued |
| 40MG;EQ 100MG BASE | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.